Annual Drug Patent Expirations for CABOMETYX
Cabometyx is a drug marketed by Exelixis Inc and is included in one NDA. It is available from one supplier. There are six patents protecting this drug.
Drug patent litigation for CABOMETYX.
This drug has one hundred and fifty-four patent family members in twenty-nine countries.
The generic ingredient in CABOMETYX is cabozantinib s-malate. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
